News Sentiment

KMTS sentiment intelligence

Kestra Medical Technologies, Ltd. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 25.99 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

77/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-3.7% over one week, +24.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

Kestra Medical Technologies (KMTS) Could Be 31% Overvalued As Earnings And 2027 Guidance Land

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 77/100 classification
One-week reaction -3.7% Price reacting lower
Trend fit Trend inactive 24.7% over four weeks
Fair value 17.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 32
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
TradingView 7
Market source 5
MarketBeat 3
Investing.com 3
marketscreener.com 3
GlobeNewswire 3
Moomoo 2

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 19
Analyst action 7
Guidance 2
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Simply Wall Street Direct company coverage

Kestra Medical Technologies (KMTS) Could Be 31% Overvalued As Earnings And 2027 Guidance Land

Kestra Medical Technologies (KMTS) shares are under scrutiny after recent earnings, 2027 revenue guidance, and a new term loan facility. Despite a significant 1-year share price increase of 60.4%, the analysis suggests the company might be 31% overvalued, with a fair value estima

Tone
Negative 30/100
Event
Earnings
Published
16 Jul 2026 00:12
Source
Simply Wall Street
Stock Titan Direct company coverage

Kestra Medical (NASDAQ: KMTS) investor Brian Webster plans 15,000-share sale

Brian Webster, an investor in Kestra Medical Technologies, Ltd. (NASDAQ: KMTS), has filed a notice for the potential sale of 15,000 common shares valued at $336,609.41. These shares were initially acquired on January 1, 2026, through a restricted share issuance as part of the com

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:12
Source
Stock Titan
MarketBeat Direct company coverage

Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Down 8.7% After Earnings Miss

Kestra Medical Technologies (NASDAQ:KMTS) saw its stock price fall 8.7% after reporting a quarterly EPS of -$0.67, missing analyst expectations. Despite the earnings miss, the company's revenue reached $28.64 million, and it secured a $200 million non-dilutive term loan facility

Tone
Negative 35/100
Event
Earnings
Published
15 Jul 2026 14:12
Source
MarketBeat
TradingView Direct company coverage

Kestra Medical Technologies, Ltd. Stock 12‑Month Price Target Raised to $28.43, Implies 18% Upside

Kestra Medical Technologies, Ltd. (KMTS) has seen its average 12-month price target increased from $27.71 to $28.43 by 7 analysts, suggesting an 18% potential upside from its July 14th closing price. The analyst consensus remains a "Buy," with 6 analysts recommending Buy and 1 re

Tone
Positive 76/100
Event
Analyst action
Published
15 Jul 2026 10:12
Source
TradingView
TradingView Direct company coverage

KESTRA MEDICAL TECHNOLOGIES, LTD. FY 2026: Revenue $95.1M, Net income $(131.6M) — 10-K Summary

Kestra Medical Technologies, Ltd. (KMTS) reported fiscal year 2026 revenue of $95.1 million, a 59% increase year-over-year, alongside a net loss of $(131.6) million, which widened from the previous year. The revenue growth was primarily driven by a 58% increase in patient volume

Tone
Negative 39/100
Event
Earnings
Published
14 Jul 2026 21:13
Source
TradingView
Market source Direct company coverage

Kestra Medical Technologies, Ltd. (KMTS) Reports Q4 Loss, Tops Revenue Estimates

Kestra Medical Technologies, Ltd. (KMTS) reported a Q4 loss of $0.67 per share, which was worse than the Zacks Consensus Estimate of a $0.59 loss, marking a -13.56% surprise. However, the company surpassed revenue estimates, posting $28.64 million, exceeding the consensus by 8.05

Tone
Negative 42/100
Event
Earnings
Published
14 Jul 2026 21:10
Source
Market source
GlobeNewswire Direct company coverage

Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results

Kestra Medical Technologies (Nasdaq: KMTS) reported strong financial results for the fourth quarter and fiscal year ended April 30, 2026, with revenue increasing by 66% and 59% respectively, and significant gross margin expansion. The company's ASSURE® system protected 18,000 pat

Tone
Positive 70/100
Event
Earnings
Published
14 Jul 2026 20:13
Source
GlobeNewswire
Stock Titan Direct company coverage

Kestra Medical (Nasdaq: KMTS) adds $200M loan as revenue surges 59%

Kestra Medical Technologies (KMTS) secured a five-year senior secured term loan facility of up to $200 million with Pharmakon Advisors, with the initial Tranche A of $75 million funding on July 10, 2026. The company reported significant revenue growth for fiscal year 2026, reachi

Tone
Positive 62/100
Event
Earnings
Published
14 Jul 2026 20:13
Source
Stock Titan
The Manila Times Direct company coverage

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies has secured up to $200 million in non-dilutive financing through a five-year term loan facility with Pharmakon Advisors, LP. This financing strengthens Kestra's balance sheet, reduces its cost of capital, and provides significant flexibility to invest

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:13
Source
The Manila Times
Investing.com Direct company coverage

Kestra Medical secures $75M loan facility with Pharmakon

Kestra Medical Technologies has secured a five-year term loan facility of up to $200 million with funds managed by Pharmakon Advisors, LP. This financing includes an initial $75 million tranche, with additional tranches available based on revenue milestones or for acquisitions. T

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Jul 2026 20:13
Source
Investing.com
Moomoo Direct company coverage

Press Release: Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies has secured up to $200 million in non-dilutive financing from a fund managed by leading global investment firm Carlyle. This significant funding will support Kestra's growth, expand its commercial efforts for the Assure® Wearable Cardioverter Defibrill

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:12
Source
Moomoo
TradingView Direct company coverage

ETFs Investing in Kestra Medical Technologies Ltd. Stocks

This article lists various ETFs that currently hold stocks of Kestra Medical Technologies Ltd. (KMTS). It provides a table detailing each ETF's market value, weight, issuer, management style, focus, expense ratio, AUM, price change percentage, relative volume, and 3-year NAV tota

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:41
Source
TradingView
TradingView Direct company coverage

KMTS Q4'25 Earnings: revenue estimate is 26.48M USD

Kestra Medical Technologies, Ltd. (KMTS) is scheduled to release its Q4'25 earnings on July 14, before market open. The company anticipates revenues of $26.48 million USD and an EPS of -$0.59 for the quarter. This article provides a detailed look at past revenue and EPS figures,

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 11:10
Source
TradingView
Finviz Direct company coverage

KMTS - Kestra Medical Technologies Ltd Options

This article provides a detailed financial overview of Kestra Medical Technologies Ltd (KMTS), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, analyst recommendations, and othe

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 16:10
Source
Finviz
Stock Titan Direct company coverage

Kestra Medical (KMTS) CBO adds 227 ESPP shares, now holds 42,488

Kestra Medical Technologies' Chief Business Officer, Timothy P. Moran, purchased 227 shares of common stock through the company's 2025 Employee Stock Purchase Plan (ESPP) on June 30, 2026, at a price of $21.55 per share. This transaction, which was exempt under Rule 16b-3, increa

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:09
Source
Stock Titan